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Summary
We report here a case of eyelash growth abnormality developing in a patient with 
primary open-angle glaucoma when treatment was switched from latanoprost (LAT) 
ophthalmic solution to bimatoprost (BIM) ophthalmic solution. The patient was a 
60-year-old woman with glaucoma of the right eye. No eyelash growth abnormality 
was evident during the 8-month use of the glaucoma medication LAT ophthalmic 
solution, a prostaglandin F2α derivative. After 8 months, narrowing of the visual field 
continued and treatment was switched to BIM ophthalmic solution, also a 
prostaglandin F2α de-rivative. This change led to improvements on visual field tests 
and in the control of in-traocular pressure, but after 6 months of BIM treatment use 
eyelash growth abnormality appeared. 
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Summary（和文）
　原発開放隅角緑内障患者に対して　ラタノプロスト（LAT）点眼液からビマトプラス
ト（BIM）点眼液に切り替えて治療を行なったところ、睫毛の異常が認められた一症例
を経験したので報告する。症例は、60歳代女性で右目緑内障患者である。患者は、緑内
障治療薬であるプロスタグランジンF2α誘導体薬剤LAT点眼液の使用開始から８ヶ月間
では睫毛の異常を認めなかった。その後、視野狭窄の進行が認められ、プロスタグラン
ジンF2α誘導体薬剤であるBIM点眼液に変更した。変更後、眼圧コントロール及び視野
検査の改善がみられたが、BIM点眼液を使用開始後６ヶ月目で睫毛の異常が認められた。
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Introduction
Glaucoma is an eye disease involving characteristic changes to the optic nerve and 
visual field and associated functional and structural abnormalities of the eye. Optic 
nerve damage can usually be improved or controlled by adequately lowering 
intraocular pressure (IOP). Disturbance of visual function has a major impact on the 
patient's quality of life, but when treating the patient it must be also remembered that 
quality of life can be impaired by treatment-related adverse reactions and 
complications as well as the social and economic burden of hospital visits and 
admissions, anxiety over loss of eye-sight, among other factors. At present, the most 
reliable method of treatment is consid-ered to be reduction of IOP, and ophthalmic 
solutions based on β-blockers or prosta-glandins are used as the first-line 
pharmaceutical treatment option owing to their effec-tiveness in lowering IOP.
The prostaglandin-related drug bimatoprost ophthalmic solution 0.03% (Lumigan®; 
hereafter 'BIM eye drops') is a new prostamide derivative synthesized by the US com-
pany Allergan. Because of a powerful effect in lowering IOP at a dose of one drop per 
eye per day, BIM eye drops were approved in the US in March 2001 for the 
indications of primary open-angle glaucoma and ocular hypertension and have 
subsequently been approved in 88 countries (as of August 2010). In Japan, BIM eye 
drops were approved for glaucoma and ocular hypertension in July 2009 1）. Because 
BIM eye drops have been proven to be non-inferior to latanoprost 0.005% ophthalmic 
solution (Xalatan®; hereafter 'LAT eye drops'), they are frequently used in clinical 
practice, particularly for non-responders to LAT eye drops 1–4）.
Here we report a case of eyelash growth abnormality in a patient whose treatment 
was switched from LAT eye drops to BIM eye drops. 
Case report
Patient: 60-year-old woman
Occupation: Pharmacist 
Chief complaint: Eyelash growth abnormality of the right eye 
Previous history: Ovarian cancer, sarcoidosis, psoriasis vulgaris 
History of current illness: The patient noticed a sudden narrowing of the visual field in 
July 2008 and was told by her physician that she had high intraocular pressure. She 
was referred to a university hospital and was diagnosed with glaucoma of the right 
eye with an IOP of 48 mmHg. Uveitis was also suspected. Treatment was started with 
carteolol hydrochloride ophthalmic solution 1% and fluorometholone eye drops 0.1%.
Clinical course: In October 2008, additional treatment was started with brinzolamide 
eye drops 1% and LAT eye drops 0.005% because there was no significant lowering of 
IOP. In February 2009, IOP had stabilized at 14–18 mmHg. In June 2009, LAT eye 
drops were stopped because IOP control and visual field tests were both good. In 
March 2010, additional treatment with BIM eye drops 0.03% was started because 
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visual field tests showed slight progression of visual field narrowing. In April 2010, 
IOP had stabilized at 13–18 mmHg. There were no adverse reactions or other 
problems associated with the use of eye drops. In September 2010, IOP was stable but 
the patient complained to her pharmacist of an abnormality of the eyelashes of the 
right eye. At a subsequent outpatient appointment, the physician confirmed a 
difference in length between the left and right eyelashes, that is the length of right 
ones more about 5mm longer than that of left ones (Fig.1). Treatment with BIM eye 
drops was continued and IOP stabilized, but the eyelashes remained at the length 
confirmed in September 2010.
Fig. 1． The eyelash growth abnormality in 60-year-old woman after using of 
BIM eye drops. The length of right eyelashes more about 5mm longer 
than that of left ones
Discussion
The eyelash growth abnormality in this patient was not seen during the 8-month use 
of LAT eye drops and developed only 6 months after changing to BIM eye drops. Pre-
vious basic research on PGF2 derivatives such as LAT has shown that these chemicals 
induce eyelash growth through triggers such as shifting to the growth phase of the 
fol-licular development cycle due to extracellular matrix (ECM) remodeling, and 
promoting hair growth through increased blood flow. BIM may also promote eyelash 
growth using a similar mechanism of action 6, 7）.
In regard to the incidence of eyelash abnormalities associated with BIM eye drops, a 
randomized clinical trial comparing IOP reduction in glaucoma patients treated for 6 
months with either BIM eye drops or LAT eye drops reported a statistically 
significant difference between eyelash abnormalities in the two groups, with 
abnormalities seen in 14 of 133 subjects (10.5%) in the BIM eye drops group and in 0 of 
136 subjects (0%) in the LAT eye drops group 8）. Another randomized clinical trial 
comparing IOP reduction in glaucoma patients treated for 6 months with either BIM 
eye drops or LAT eye drops in combination with timolol eye drops also reported a 
significant difference between the two groups, with eyelash abnormalities seen in 12 of 
― 43 ―
A case of eyelash growth abnormality 
after switching from latanoprost ophthalmic solution to bimatoprost ophthalmic solution
28 subjects (42.8%) in the BIM eye drops group and in 0 of 28 subjects (0%) in the 
LAT eye drops group9）. These results indicate that the incidence of eyelash 
abnormalities as an adverse reaction is remarkably higher with BIM eye drops than 
with LAT eye drops.
Turning to the causal relationship between BIM eye drops and eyelash abnormalities, 
we reviewed the timing of onset of eyelash abnormalities and degree of severity at dif-
ferent observation periods in long-term administration studies of BIM eye drops. The 
results showed that this adverse reaction occurred frequently from the start of admin-
istration to week 12, but was also seen from week 12 to week 28 1, 2）. These results 
strongly support a causal relationship between our patient's use of BIM eye drops and 
her eyelash growth abnormality.
The package insert for BIM eye drops includes the precautionary statement that if 
the eye drops come into contact with the skin of the eyelid during application, they 
should be wiped away or the face should be washed to prevent or reduce excessive 
hair growth around the eye. Our patient was a pharmacist who was fully aware of and 
com-plied with this precaution, yet she was unable to avoid this eyelash growth 
abnormality as a reaction to BIM eye drops.  
When issuing guidance on the use of BIM eye drops to patients in the pharmacy, the 
pharmacist should explain the risk of developing an eyelash growth abnormality. If 
such an abnormality becomes a problem in the patient's daily life or affects their 
appearance, the pharmacist should also suggest the patient consult an ophthalmologist 
as well as ad-vise her on measures such as trimming or removing eyelashes.
Written informed consent was obtained from the patient for publication of this case 
report.
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